Clinical Trials
25 trialsNCT06525220 2026-06-02
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Phase 3 Recruiting
NCT06788990 2026-06-02
FORTIFI-HN01
Bicara Therapeutics
Phase 2/3 Recruiting
NCT04534205 2026-05-22
AHEAD-MERIT
BioNTech SE
Phase 2/3 Recruiting
NCT07601737 2026-05-22
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT07264075 2026-05-20
ILLUMINE
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Recruiting
NCT05420948 2026-05-12
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
University of Chicago
Phase 2 Recruiting
NCT05358548 2026-04-30
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT07213934 2026-04-15
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 1/2 Recruiting
NCT07501650 2026-03-30
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
Thomas Jefferson University
Phase 1 Recruiting
NCT04585750 2026-03-12
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Phase 1/2 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT06736379 2026-01-20
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
Phase 1 Recruiting
NCT06998069 2025-12-30
Head and Neck Cancer Study Project in the Geriatric Population
Brown University
Phase 3 Recruiting
NCT03556228 2025-12-11
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1/2 Recruiting
NCT06912087 2025-12-02
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
Phase 1 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT04429542 2025-08-15
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
Phase 1 Recruiting
NCT05726370 2025-06-22
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05144698 2025-05-14
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
Phase 1/2 Recruiting
NCT06549946 2025-01-30
IXACT
Psivac Ltd
Phase 1/2 Recruiting
NCT04857164 2025-01-28
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06366451 2025-01-20
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Presage Biosciences
Phase EARLY_PHASE1 Recruiting
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT06265025 2024-03-21
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
GeneMedicine Co., Ltd.
Phase 1/2 Recruiting
NCT05025813 2022-08-01
DESQUAMATE
Queensland Health
Phase 2 Recruiting